Purpose: The purpose of this study is to define the prevalence of vitamin B 12 deficiency in a type 2 diabetic population within a primary care practice. Metformin use and advanced age are associated with vitamin B 12 deficiency and often present in type 2 diabetic patients, yet the prevalence of vitamin B 12 deficiency in the diabetic population is unknown.
Type 2 diabetes is frequently treated by primary care physicians who must be able to manage both the disease and its multiple comorbidities. Vitamin B 12 deficiency is a potential comorbidity that is often overlooked, despite the fact many diabetic patients are at risk for this specific disorder. For example, many diabetic patients are treated with metformin, a medication that lowers serum vitamin B 12 levels [1] [2] [3] [4] and is associated with vitamin B 12 deficiency. 1, [5] [6] [7] [8] In addition, almost half of all diabetic patients are older than 60, an age group in which the prevalence of metabolically confirmed B 12 deficiency ranges from 12% to 23%. 9 -11 Because of these risk factors, defining the prevalence in the diabetic population may help determine whether primary care physicians should consider screening for B 12 deficiency in diabetic patients. According to the World Health Organization's criteria for screening, a condition may be worthwhile to screen for if it is an important health problem and if there are tests available to detect the condition at an early, treatable stage. betic patients older than 40 have impaired sensation in the feet. 13 Unfortunately, the symptoms of diabetic neuropathy overlap with the paresthesias, impaired vibration sense, and impaired proprioception associated with B 12 deficiency.
14 As a result, B 12 deficiency-induced nerve damage may be confused with or contribute to diabetic peripheral neuropathy. 15 Identifying the correct etiology of neuropathy is crucial because simple vitamin B 12 replacement may reverse neurologic symptoms inappropriately attributed to hyperglycemia.
Vitamin B 12 deficiency is traditionally diagnosed by laboratory findings of low serum vitamin B 12 levels, typically in the setting of megaloblastic anemia. However, subclinical B 12 deficiency often presents with normal serum B 12 levels and hematologic parameters. 16 Elevated methylmalonic acid and homocysteine levels improve the diagnosis of tissue B 12 deficiency [17] [18] [19] and may identify patients with deficiency at an early, reversible stage. Using these more specific diagnostic markers, we conducted a cross-sectional study to determine the extent of B 12 deficiency in the diabetic population. Our primary aim was to define the prevalence of serologic B 12 deficiency in the type 2 diabetic population. Our secondary aim was to assess for associated factors, such as age and metformin use, to help predict such deficiency.
Methods

Participants
This study used a descriptive, cross-sectional design to determine the prevalence of vitamin B 12 deficiency among a sample of approximately 4000 type 2 diabetic patients cared for by the Madigan Army Medical Center (MAMC) Family Medicine Clinic (FMC). The MAMC Institutional Review Board approved the study.
Enrollment
Inclusion criteria were patients aged 45 years and older with the diagnosis of type 2 diabetes. The MAMC FMC appointment schedule was used daily to identify potential volunteers. Study personnel subsequently solicited diabetic patients presenting for a diabetic appointment for enrollment into the study. Diabetic patients that declined participation in the study were not tracked. 
Measurements
On enrollment, participants presented to the laboratory for phlebotomy. The individual blood samples were initially assayed within the MAMC laboratory for B 12 and folate levels and then stored at Ϫ70°C. B 12 levels Ͻ100 pg/mL were considered deficient whereas B 12 levels Ͼ350 pg/mL were considered normal. Blood levels of B 12 between 100 and 350 pg/mL were considered indeterminate 20 -22 and the corresponding blood specimens were sent to Quest Diagnostics for determination of methylmalonic acid (reference range, 88 -243 nmol/L) and homocysteine levels (reference range, 5.4 -11.9 nmol/L). Specimens with methylmalonic acid and/or homocysteine levels above the upper limit of the laboratory reference range were considered elevated and indicative of B 12 deficiency. Study staff notified and gave recommendations for treatment to all B 12 -deficient patients and their primary care providers.
Statistical Analysis
Power analysis indicated that 187 to 232 patients were required to determine a 15% to 20% prevalence (with 95% CI of Ϯ5%) of vitamin B 12 deficiency in FMC type 2 diabetic patients.
All statistics were done with SPSS software version 12.0 (SPSS, Inc., Chicago, IL 
Results
A total of 203 patients enrolled in the study. Eight patients were excluded: 2 had ileum resections, 2 were younger than 45 years of age, 2 were taking supplemental B 12 Ͼ500 mcg/day, one had a gastrectomy, and one had Crohn's disease. The remaining 195 patients were included in the final analysis (Table 1) . Serum B 12 levels ranged from 91 to 2818 pg/ mL. Only one individual had a B 12 level Ͻ100 pg/mL; 79 had intermediate levels between 100 and 350 pg/mL and required confirmatory testing to assess for deficiency. Forty-three of these patients (54%) with intermediate B 12 levels had elevations of either methylmalonic acid or homocysteine, resulting in a total of 22% (n ϭ 44) of patients diagnosed with metabolic B 12 deficiency. Table 1 shows the participants' demographic data. The majority of participants took metformin and approximately half were on a dose of Ն2000 mg daily at the time of enrollment. Approximately one-third of patients took either an H 2 blocker or a proton pump inhibitor, whereas just over half took a multivitamin daily (Table 2) . Table 2 shows key variable comparisons between patients with and without B 12 deficiency. Metformin use, including both current use and history of metformin use, was not associated with B 12 deficiency. On average, patients with a B 12 deficiency suffered from diabetes for a significantly longer time than patients without a B 12 deficiency (P ϭ .04). In addition, the percentage of patients identified as having a B 12 deficiency was significantly lower among patients using a multivitamin compared with those patients who did not take a multivitamin supplement (P Ͻ .001). Only 4 patients reported taking B-complex vitamins, none of which had B 12 deficiency. When a second 2 was performed defining at risk for B 12 deficiency as any serum B 12 level Ͻ350 pg/mL, the results indicated that patients using metformin were statistically at higher risk for B 12 deficiency (P ϭ .04). A series of further analyses were subsequently performed to determine whether metformin dose was associated with B 12 deficiency. In this study population, there was no statistically significant association between the average prescribed metformin dosage for patients with B 12 deficiency (mean, 1776.32; SD, 578.06) and patients without B 12 deficiency (mean, 1602.52; SD, 554.48), as shown by t(155) ϭ 1.67 (P ϭ .09).
A t test was conducted to determine whether any difference existed in the B 12 levels of individuals currently using metformin versus those who were not. Patients taking metformin had statistically significant lower levels of B 12 (425.99 pg/mL vs 527.49 pg/mL; P ϭ .01).
Multivariate logistic regression analysis showed that in this study sample, use of a multivitamin significantly reduced odds of B 12 deficiency (odds ratio, 0.31; 95% CI, 0.15-0.63). Use of H 2 blockers or proton pump inhibitors, age, and metformin use were not significantly associated with B 12 deficiency.
Discussion
This is the first cross-sectional study we are aware of that was specifically designed to define the prevalence of B 12 deficiency in patients with type 2 diabetes. In our cohort, we identified 22% of type 2 diabetic patients with B 12 deficiency. Although it is possible to deduce the prevalence of B 12 deficiency in diabetic patients from previous studies, 7 we feel our broad inclusion criteria provided an estimate that is more generalizable to the entire type 2 diabetic population. With a prevalence of 22%, physicians will need to consider the comorbid effects of B 12 deficiency in a population already predisposed to neuropathic complications. More investigations are required to chart the full clinical impact of deficiency in these patients.
Despite that the clinical significance of a 22% prevalence of B 12 deficiency in the diabetic population is unknown, the impact B 12 deficiency may have as a cause of peripheral neuropathy in this population should be explored. Sixty percent to 70% of diabetic patients have mild to severe forms of nervous system damage, 13 the most common being peripheral neuropathy. The relatively high prevalence of B 12 deficiency found in this study makes it likely that at least a portion of peripheral neuropathy cases in diabetic patients may be attributed to B 12 deficiency. Previous studies have demonstrated that supplemental vitamin B 12 improved somatic and autonomic symptoms of diabetic neuropathy. 23, 24 Testing for, and treating, B 12 deficiency in those patients with neuropathy may lead to improved clinical outcomes. Clinical trials are needed to further evaluate this link.
To improve the diagnosis of B 12 deficiency, we measured methylmalonic acid and homocysteine blood levels. These markers of B 12 deficiency have been shown to improve the sensitivity and specificity for detecting B 12 deficiency. More importantly, these markers may discover tissue B 12 deficiency in an early, asymptomatic, and reversible state. Other studies have used methylmalonic acid and homocysteine levels to define the prevalence of B 12 deficiency in the elderly, but not in the diabetic population. These studies demonstrate a prevalence of B 12 deficiency in the elderly that ranges from 12% to 23%. 9 -11 Although the prevalence of B 12 deficiency in our diabetic patients was in line with these results, it is important to note that the average age of our population was approximately 15 years younger than the average age of the elderly volunteers enrolled in these other studies. In addition, both bivariate and multivariate analyses demonstrated that age was not significantly associated with B 12 deficiency. This suggests that type 2 diabetes, not age, may account for the 22% prevalence of B 12 deficiency. Unfortunately, the ability to compare our prevalence results to the general population is limited because there are no published studies that examine the prevalence of B 12 deficiency in the general population using methylmalonic acid and homocysteine levels for diagnosis.
Patients on chronic metformin therapy seem to be at increased risk for B 12 deficiency. Its use is associated with lower serum vitamin B 12 levels [1] [2] [3] [4] 6 and megaloblastic anemia. 1 Several studies associate metformin use with established clinical B 12 deficiency. 1, 5, 7 In fact, higher doses and longer treatment with metformin seem to be risk factors for such deficiency. 25 Although we found that patients using metformin had lower B 12 levels, we did not find metformin use to be associated with overt B 12 deficiency. In addition, there were no statistically significant metformin dose-dependent relationships, despite a trend between higher dosages of metformin use and B 12 deficiency. Our study was not designed nor powered to find these secondary associations. As part of a post hoc analysis we did look at diabetic patients at risk for B 12 deficiency to determine whether there was a significant association with metformin use. Current metformin use was associated with a significantly higher risk for B 12 deficiency when defined as a serum B 12 level Ͻ350 pg/mL. Patients with B 12 levels Ͻ350 pg/ mL may be at risk for B 12 deficiency becuase tissue deficiency may occur despite normal serum B 12 levels. 10,20 -22 Identification of patients "at risk" for B 12 deficiency as those with serum B 12 Ͻ350 pg/mL may help the clinician define a level to test for B 12 deficiency using specific tissue markers, especially among diabetics who are using metformin.
Our multivariate analysis looked for specific associations for B 12 deficiency. We entered into our model known and potential risk or protective factors for B 12 deficiency. Multivitamin use seemed to protect diabetic patients from B 12 deficiency. The effect of multivitamins raising serum B 12 levels is documented in the literature. Randomized trials in adults taking 6 to 9 mcg of B 12 daily show effects of higher serum B 12 levels compared with placebo. 26, 27 There are no known studies specifically evaluating whether a daily multivitamin prevents B 12 deficiency. Our findings may be noteworthy because conventional treatment of B 12 deficiency is with high dose oral supplementation or B 12 injections. 28 Yet, most multivitamin formulations typically contain 6 to 25 mcg of supplemental B 12 , 29, 30 which seemed to be enough to protect against B 12 deficiency in type 2 diabetic patients. Further research needs to be conducted before the validity of multivitamin use to prevent against B 12 deficiency is confirmed. Other factors known to increase risk for B 12 deficiency, such as advanced age and acid blocker use, were not significantly associated with B 12 deficiency.
There were several limitations to our study. Our cohort was a sample population from a military health care system. MAMC has been recognized as an innovator in the chronic care model of diabetes. Subsequently, most patients had well-controlled diabetes. In populations with poorer glycemic control, our study may not be generalizable because the rates of metformin use may not be similar. However, a population with poorer glycemic control is at higher risk for neuropathy and may benefit even more from early identification of concomitant B 12 deficiency. In addition, we only included diabetics older than 45, consistent with the age group of the majority of the type 2 diabetic population in the United States. 13 Overall, we feel our participants represent typical primary care diabetic patients who present to an outpatient clinic for ongoing care.
The cross-sectional nature of our study limits us to describing a population. Therefore, the findings relevant to our secondary aims were limited to associations. The primary objective, however, was to define the prevalence of B 12 deficiency in the diabetic population, for which a cross-sectional study is appropriate. Additional studies will be needed to prove causation. In addition, defining B 12 deficiency based solely on biochemical markers remains controversial. [31] [32] [33] Although elevations in methylmalonic acid have been correlated with clinical manifestations of B 12 deficiency, 17, 18 we did not evaluate for evidence of megaloblastic anemia or neuropathic disease. Therefore, the clinical significance of metabolically confirmed B 12 deficiency in our patient group is unknown. Finally, the B 12 -deficient patients identified in our study were not followed for treatment effect with supplemental vitamin B 12 or to evaluate for normalization of B 12 and methylmalonic acid levels. Such follow-up would have helped confirm the diagnosis of vitamin B 12 deficiency.
Conclusion
Finding a prevalence of 22% raises the question of whether to screen for B 12 deficiency in all patients. No studies that we are aware of have looked at outcomes for treating asymptomatic B 12 deficiency, so the benefit of such treatment is unknown. Primary care physicians should recognize that up to one fifth of their diabetic patients may have B 12 deficiency; they should consider B 12 deficiency in the differential diagnosis when managing comorbidities of diabetes, especially neuropathy. Further studies need to be undertaken to determine whether screening and subsequent treatment can prevent peripheral neuropathy from developing in patients with type 2 diabetes before advocating for universal screening. Finally, empiric treatment with a multivitamin should also be explored as a method for reducing the incidence of B 12 deficiency in the type 2 diabetic population.
